Presenting on Emerging Growth Conference 88 Day 1 on December 10; Register to live stream Dec 9, 2025 07:00AM
Presenting on Emerging Growth Conference 86 Day 2 September 25; Register to live stream Sep 24, 2025 07:00AM
Presenting on Emerging Growth Conference 85 Day 1 on August 20; Register to live stream Aug 19, 2025 07:00AM
Presenting on Emerging Growth Conference 84 Day 2 on July 17; Register to live stream Jul 16, 2025 07:00AM
Coca Access and Benefit Sharing Agreement Authorized by Peru's National Institute of Agrarian Innovation (INIA) Supports Research Efforts of Jaguar Health and Filament Health Joint Venture, Magdalena Jul 8, 2025 09:00AM
View Older Stories

Jun 17, 2025 07:00AM Presenting on Emerging Growth Conference 83 Day 2 on June 18; Register to live stream
Mar 26, 2025 07:00AM Presenting on the Emerging Growth Conference 80 Day 2 on March 27 Register Now
Feb 18, 2025 07:00AM Presenting on the Emerging Growth Conference 79 Day 1 on February 18 Register Now
Feb 6, 2025 10:00AM Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO & Investor Conference
Jan 7, 2025 10:00AM Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present January 12 at the Annual Neuroscience Innovation Forum
Dec 19, 2024 09:00AM Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating Mental Health Indications
Dec 4, 2024 07:00AM Presenting on the Emerging Growth Conference 77 Day 2 on December 5th Register Now
Oct 10, 2024 10:00AM Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present October 16 at BIO Investor Forum
Aug 20, 2024 10:00AM Key Collaborator of Jaguar Health Joint Venture Magdalena Biosciences Receives Prestigious Alzheimer's Association Award
Aug 2, 2024 10:00AM Elaine Elisabetsky, PhD, Member of Jaguar Health's Mental Health Entheogen Therapeutics Initiative, to Speak August 2nd About Plant-Based Medicines Used to Manage Schizophrenia at the University of Il
Jun 7, 2024 04:15PM Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Jun 7, 2024 04:15PM Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Jun 7, 2024 04:15PM Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 29, 2024 08:30AM Jaguar Health Executes Out-License Deal with Joint Venture Magdalena Biosciences for Botanical Drug Candidate for Schizophrenia
May 28, 2024 08:30AM Investigator-Initiated Trial of Jaguar Health’s Crofelemer Yields Positive Results for Functional Diarrhea
May 28, 2024 08:30AM Investigator-Initiated Trial of Jaguar Health’s Crofelemer Yields Positive Results for Functional Diarrhea
May 23, 2024 08:30AM Jaguar Health to Initiate Commercial Footprint in Cancer Supportive Care at American Society of Clinical Oncology (ASCO) Annual Meeting with Exhibit Booth for FDA-Approved Gelclair Oral Mucositis Prod
May 23, 2024 08:30AM Jaguar Health to Initiate Commercial Footprint in Cancer Supportive Care at American Society of Clinical Oncology (ASCO) Annual Meeting with Exhibit Booth for FDA-Approved Gelclair Oral Mucositis Prod
May 23, 2024 08:30AM Jaguar Health to Initiate Commercial Footprint in Cancer Supportive Care at American Society of Clinical Oncology (ASCO) Annual Meeting with Exhibit Booth for FDA-Approved Gelclair Oral Mucositis Prod
May 17, 2024 04:18PM Jaguar Health (JAGX) Announces 1:60 Reverse Share Split
May 17, 2024 04:15PM Jaguar Health, Inc. Announces Reverse Stock Split
May 14, 2024 08:00AM Jaguar Health Reports First Quarter 2024 Financial Results
May 13, 2024 12:35PM REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates
May 9, 2024 10:35AM Jaguar Health Announces Submission of Clinical Trial Applications for Crofelemer for the Rare Disease Indications Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome (SBS) in Europe
May 8, 2024 08:30AM Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates
May 6, 2024 08:34AM Jaguar Health's (JAGX) Crofelemer Approved by the FDA for Chemotherapy-Induced Diarrhea in Dogs
May 6, 2024 08:30AM Crofelemer, Jaguar Health’s Prescription Drug Conditionally Approved by the FDA for Chemotherapy-Induced Diarrhea in Dogs, is the Subject of the Company’s Investigational New Animal Drug Applicati
Apr 29, 2024 08:30AM Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Pediatric Gastroenterology Conference in Abu Dhabi and Panel Discussion About Microvillus Inclusion Disease (MVID)
Apr 22, 2024 08:45AM Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company’s Expanding Focus on Cancer Supportive Care
Apr 18, 2024 08:42AM Jaguar Health (JAGX) Appoints Miller Collis as SVP of Growth Strategy
Apr 18, 2024 08:30AM Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care
Apr 16, 2024 08:33AM Jaguar Health (JAGX) Licenses FDA-Approved Oral Mucositis Product for U.S. Market
Apr 16, 2024 08:30AM Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
Apr 9, 2024 04:15PM Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders
Apr 8, 2024 08:30AM Jaguar Health Granted Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement
Apr 2, 2024 08:56AM Jaguar Health (JAGX) Appoints Massimo Radaelli as President of Jaguar International
Apr 2, 2024 08:30AM Jaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar International
Apr 1, 2024 08:00AM Jaguar Health Reports 2023 Financial Results
Mar 27, 2024 08:30AM Jaguar Health to Hold Investor Webcast Monday, April 1st at 8:30 AM Eastern Regarding Q4 2023 Financials & Corporate Updates
Mar 20, 2024 08:30AM GEN to Commercialize Jaguar Health's Crofelemer in Turkey and Eight Neighboring Countries and Invest $2 Million in Jaguar Stock at 75% Premium to Market
Feb 23, 2024 08:34AM Jaguar Health (JAGX) Granted Hearing on Nasdaq Listing Compliance
Feb 23, 2024 08:30AM Jaguar Health Requests and Receives Hearing on Nasdaq Listing Compliance
Feb 15, 2024 08:33AM Jaguar Health (JAGX) Announces FDA Agrees with Clinical Trial Protocol for Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea in Dogs
Feb 15, 2024 08:30AM Jaguar Health Announces FDA Agrees with Clinical Trial Protocol for Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Feb 14, 2024 08:30AM Jaguar Health Donates Supply of Mytesi to Humanitarian Aid Organization Direct Relief
Feb 12, 2024 08:33AM Jaguar Health (JAGX) Announces Submission of Orphan Drug Designation Application to FDA for Crofelemer for Cholera-Related Diarrhea
Feb 12, 2024 08:30AM Jaguar Health Announces Submission of Orphan Drug Designation Application to the FDA for Crofelemer for Cholera-Related Diarrhea
Jan 30, 2024 08:45AM Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Study Indicates Psychoactive Activity of Medicinal Plant Utilized for Centuries by Indigenous Peoples in Tropical Regi
Jan 29, 2024 08:30AM Jaguar Health to Present January 31 at The Microcap Conference and Participate in a Fireside Chat February 1 at the Lytham Partners Investor Select Conference
Jan 25, 2024 08:30AM Dog Study Published in PLOS ONE Shows Statistically Significant Results for Use of Jaguar Health’s Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea (CTD)
View Older Stories